AbbVie’s steerage for the subsequent few years implies strong income development.
A number of the firm’s merchandise are performing even higher than anticipated.
AbbVie’s valuation and dividend program seal the deal.
10 shares we like higher than AbbVie ›
Whereas the healthcare sector has not saved tempo with broader equities up to now, some business leaders have. AbbVie(NYSE: ABBV), a pharmaceutical large, is one among them. The corporate’s shares are up by 29% this 12 months. The drugmaker has constantly overwhelmed the market (with some exceptions) because it grew to become publicly traded in 2013. However can it maintain that streak going heading into 2026? Let’s discover out whether or not AbbVie is a purchase, promote, or maintain for the subsequent 12 months.
One key motive AbbVie has outperformed the market this 12 months is that it has carried out effectively financially. By the primary 9 months of the 12 months, the corporate’s income elevated by 8% 12 months over 12 months to $44.5 billion. Adjusted earnings per share declined to $7.29 (down from $7.96), primarily resulting from acquisition-related costs. There’s not a lot to fret about there. AbbVie ought to keep that momentum heading into 2026 and, for that matter, for the remainder of the last decade. In early 2024, the corporate launched its long-term steerage, projecting excessive single-digit income development by 2029.
Picture supply: Getty Pictures.
Since then, a number of issues have modified. Most notably, whereas AbbVie predicted mixed 2027 gross sales of over $27 billion for Skyrizi and Rinvoq — two immunology medicines and its largest development drivers — it has since added $4 billion to that projection. Skyrizi and Rinvoq’s sturdy performances are one key motive AbbVie ought to carry out effectively not less than till the tip of the last decade. In the meantime, AbbVie expects its oncology income to start out transferring in the proper course once more subsequent 12 months.
A number of different development drivers will contribute, together with schizophrenia therapy Vraylar and Qulipta, a drugs for migraines. Lastly, AbbVie’s Humira, which misplaced patent exclusivity in 2023, ought to fade into full irrelevance. It nonetheless generated $3.3 billion in gross sales for the corporate by the primary 9 months of 2025, turning into its third best-selling product, however its income declined by 55% 12 months over 12 months.
Now, there have been some detrimental developments for AbbVie. Most notably, the U.S. authorities has focused Vraylar for drug worth negotiations. Negotiated costs will take impact in 2027. Nonetheless, administration doesn’t anticipate this issue to have a big influence on its long-term steerage. Lastly, AbbVie expects no lack of patent exclusivity for a serious development driver by the tip of the last decade.
So, the corporate’s prospects over the subsequent 5 years seem vivid.
AbbVie’s enterprise is performing effectively. Outcomes are sturdy, and the pipeline is powerful, with the potential for loads of extra approvals and label expansions. However are the corporate’s shares engaging at present ranges? My view is that they’re. Take into account that AbbVie is buying and selling at 16.1 occasions ahead earnings in comparison with the typical for the healthcare sector of 18.2. This might recommend that, regardless of its sturdy enterprise and wonderful medium-term outlook, AbbVie is fairly valued.
That is additionally obvious when wanting on the firm’s worth/earnings-to-growth (PEG) ratio, which is at the moment 0.4. Because the “undervalued” vary begins at 1 and under, this additionally means that AbbVie’s shares are low cost. Moreover, the corporate affords a wonderful dividend program. When factoring within the time it spent as a unit of its former father or mother firm, Abbott Laboratories, AbbVie is a Dividend King, or an organization that has supplied annual dividend raises for not less than 50 consecutive years.
AbbVie’s streak stands at 54. The corporate’s ahead yield of three% additionally seems pretty aggressive, contemplating the S&P 500 common of 1.2%. And AbbVie’s money payout ratio of 61.8% is not too excessive both. So, AbbVie has strong underlying operations, a powerful outlook by the subsequent decade, is fairly valued, and affords an distinctive dividend program. The inventory is a powerful purchase heading into 2026.
Before you purchase inventory in AbbVie, think about this:
The Motley Idiot Inventory Advisor analyst staff simply recognized what they imagine are the 10 greatest shares for traders to purchase now… and AbbVie wasn’t one among them. The ten shares that made the lower may produce monster returns within the coming years.
Take into account when Netflix made this checklist on December 17, 2004… in case you invested $1,000 on the time of our advice, you’d have $509,470!* Or when Nvidia made this checklist on April 15, 2005… in case you invested $1,000 on the time of our advice, you’d have $1,167,988!*
Now, it’s value noting Inventory Advisor’s whole common return is 991% — a market-crushing outperformance in comparison with 196% for the S&P 500. Do not miss the most recent prime 10 checklist, obtainable with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person traders for particular person traders.
See the ten shares »
*Inventory Advisor returns as of December 22, 2025
Prosper Junior Bakiny has no place in any of the shares talked about. The Motley Idiot has positions in and recommends AbbVie and Abbott Laboratories. The Motley Idiot has a disclosure coverage.
Is AbbVie a Purchase, Promote, or Maintain in 2026? was initially revealed by The Motley Idiot
